PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9367869-11	1997	When treated with p21ras inhibitor, BZA-5B, there was a moderate reversal of Wnt5a mRNA expression (2-fold) with a parallel decrease in cell growth.	BZA 5B	36-42	HRas proto-oncogene, GTPase	Homo sapiens	18-24
9690624-5	1998	Thus, TM down-regulation in c-jun-transformed cells was alleviated by inhibitors of Ras (BZA-5B) or MEK1 (PD98059).	BZA 5B	89-95	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
9367869-11	1997	When treated with p21ras inhibitor, BZA-5B, there was a moderate reversal of Wnt5a mRNA expression (2-fold) with a parallel decrease in cell growth.	BZA 5B	36-42	Wnt family member 5A	Homo sapiens	77-82
7595063-5	1995	The farnesyltransferase inhibitor BZA-5B caused a dramatic decrease in p65 prenylation, suggesting that this protein may be modified by the C15 isoprenoid farnesyl.	BZA 5B	34-40	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	71-74
8830800-5	1996	IFN-gamma-induced huGBPs in HL-60 cells were not labeled by the specific C20 isoprenoid, [3H]geranylgeraniol, but did show decreased isoprenoid incorporation in cells treated with the farnesyl transferase inhibitor BZA-5B, indicating that huGBPs in HL-60 cells are probably modified by a C15 farnesyl rather than the more common C20 lipid.	BZA 5B	215-221	interferon gamma	Homo sapiens	0-9
8662667-9	1996	Overexpression of Ha-RasV12 caused the recruitment of Raf-1 to caveolae independently of EGF stimulation, and this was blocked by the farnesyltransferase inhibitor BZA-5B.	BZA 5B	164-170	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	54-59
8557638-8	1996	The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes.	BZA 5B	35-41	mitogen activated protein kinase 3	Rattus norvegicus	64-68
8557638-8	1996	The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes.	BZA 5B	35-41	mitogen activated protein kinase 1	Rattus norvegicus	69-73
8557638-8	1996	The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes.	BZA 5B	35-41	nitric oxide synthase 2	Rattus norvegicus	91-95
8557638-8	1996	The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes.	BZA 5B	35-41	interferon gamma	Rattus norvegicus	99-108
8557638-8	1996	The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes.	BZA 5B	35-41	interleukin 1 beta	Rattus norvegicus	113-122
9169405-6	1997	Inhibition of Ras by the farnesyltransferase inhibitor BZA-5B inhibited prostaglandin synthesis in H2122 cells by decreasing expression of both cPLA2 and COX-2.	BZA 5B	55-61	phospholipase A2 group IVA	Homo sapiens	144-149
9169405-6	1997	Inhibition of Ras by the farnesyltransferase inhibitor BZA-5B inhibited prostaglandin synthesis in H2122 cells by decreasing expression of both cPLA2 and COX-2.	BZA 5B	55-61	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-159
7890759-1	1995	BZA-5B, a benzodiazepine peptidomimetic, inhibits CAAX farnesyltransferase (FTase) and blocks attachment of farnesyl groups to oncogenic and wild-type H-Ras in animal cells.	BZA 5B	0-6	HRas proto-oncogene, GTPase	Homo sapiens	151-156
7614464-0	1995	The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization.	BZA 5B	43-49	HRas proto-oncogene, GTPase	Rattus norvegicus	93-99
7961691-6	1994	These data raise the possibility that untransformed cells contain a form of Ras (K-Ras or N-Ras) whose prenylation is not inhibited by BZA-5B, thus allowing them to resist the effects of BZA-5B.	BZA 5B	187-193	NRAS proto-oncogene, GTPase	Rattus norvegicus	76-79
7961691-6	1994	These data raise the possibility that untransformed cells contain a form of Ras (K-Ras or N-Ras) whose prenylation is not inhibited by BZA-5B, thus allowing them to resist the effects of BZA-5B.	BZA 5B	187-193	KRAS proto-oncogene, GTPase	Rattus norvegicus	81-86
7961691-6	1994	These data raise the possibility that untransformed cells contain a form of Ras (K-Ras or N-Ras) whose prenylation is not inhibited by BZA-5B, thus allowing them to resist the effects of BZA-5B.	BZA 5B	187-193	NRAS proto-oncogene, GTPase	Rattus norvegicus	90-95